TNFRSF17 and plasma cell myeloma: Similarly, teclistamab targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, demonstrating potent efficacy in relapsed/refractory multiple myeloma (RRMM) (148-150).